GLP-3R: A Receptor-Signaling Research Peptide for In-Vitro Laboratories in 2026

For in-vitro laboratory research use only. Not for human consumption.

G protein-coupled receptors (GPCRs) are among the most intensively studied proteins in cell biology, and synthetic peptide ligands are central tools for studying them in vitro. GLP-3R is a synthetic peptide catalogued for laboratory research on receptor binding and intracellular signaling at class B GPCRs of the glucagon receptor family. This guide explains the receptor pharmacology concepts relevant to that work, the analytical methods used to characterize peptide research materials, and the storage and documentation practices that support reproducible in-vitro studies.

What Is GLP-3R?

GLP-3R is a synthetic peptide supplied as a lyophilized powder for in-vitro laboratory research. It is used in cell-based and biochemical assays that examine ligand binding and signaling at three related receptors:

• GLP-1R (glucagon-like peptide-1 receptor), a class B GPCR
• GIPR (gastric inhibitory polypeptide receptor), a class B GPCR of the same family
• GCGR (glucagon receptor), the founding member of the family

These three receptors share a common architecture: a large N-terminal extracellular domain that captures the C-terminal portion of a peptide ligand, and a seven-transmembrane domain that engages the ligand's N-terminal region and couples to intracellular G proteins. Because of this shared structure, a single peptide ligand can be characterized across all three receptors in parallel, which is what makes a compound like GLP-3R useful as a tool in receptor pharmacology.

GLP-3R is not approved for human use by the FDA or any comparable agency. It is sold for in-vitro laboratory research only.

The Science: Receptor Pharmacology Concepts

Class B GPCR Structure

Class B GPCRs (the "secretin family") are distinguished from the larger class A family by their extracellular domain, which is typically around 120 residues long and folds into a conserved structure stabilized by three disulfide bonds. Peptide ligands bind in a "two-domain" mode: the C-terminal part of the peptide, often helical, docks into a groove on the extracellular domain, and the N-terminal part inserts into the transmembrane core, where it triggers receptor activation.

Binding Versus Activation

In receptor pharmacology, binding (affinity) and activation (signaling) are measured separately. Radioligand or fluorescent-ligand competition assays report how strongly a peptide occupies a receptor, while functional assays report what happens inside the cell once it does. A ligand can bind strongly yet activate weakly, and the relationship between the two can differ from receptor to receptor.

Comparing Activity Across Several Receptors

When a single peptide is characterized at several related receptors, laboratories typically generate a full concentration-response curve at each receptor under matched conditions and compare the half-maximal effective concentrations (EC50) and maximal responses (Emax). Reference ligands for each receptor are run alongside so that values can be normalized. This design allows the relative activity of a test peptide at each receptor to be expressed on a common scale.

Why GLP-3R Is Used as a Research Tool in 2026

• Multi-receptor characterization: A single ligand that can be tested at three related receptors supports comparative studies of receptor activation and signaling in engineered cell lines
• Signaling-bias studies: Class B GPCRs couple to G proteins and to beta-arrestins, and multi-receptor ligands are used to examine how that balance differs between receptors
• Structural pharmacology: Peptide ligands of this family are used in structural studies of receptor-ligand complexes, including cryo-electron microscopy work on class B GPCRs

Sourcing Considerations for Researchers

When sourcing GLP-3R for laboratory research, laboratories typically consider:

• A published third-party Certificate of Analysis for the product that names the testing laboratory
• Identity confirmation (LC-MS or FTIR) consistent with the stated molecular identity
• Independent incoming verification by HPLC and an identity method where the application requires it
• A U.S.-based domestic supply chain with stated storage conditions

Excalibur Peptides is a U.S.-based research peptide supplier. GLP-3R was third-party tested by Freedom Diagnostics Testing (search code Exca2610050656), with purity by HPLC and identity by LC-MS; the COA is in our COA database and on the product page, and the search code can be entered on the testing laboratory's COA lookup page. Laboratories whose work depends on a defined specification for the specific vial in use can add their own analytical verification to their incoming inspection procedures.

All products sold by Excalibur Peptides are intended for in-vitro laboratory research use only. Not for human consumption.

Advanced Mechanistic Insights: Receptor Signaling Bias and Cellular Cross-Talk

While the primary function of glp-3-r is defined by its tri-agonist activity at the GLP-1, GIP, and glucagon receptors, advanced in-vitro research is delving into a more nuanced aspect of its mechanism: signaling bias. All three target receptors are G-protein coupled receptors (GPCRs), a vast family of transmembrane proteins that act as molecular switches. When an agonist like glp-3-r binds to a GPCR, it doesn't just turn the receptor "on"; it can preferentially activate specific downstream signaling pathways over others. This phenomenon is known as biased agonism or functional selectivity.

For a laboratory researcher, understanding the potential for signaling bias is critical for experimental design and data interpretation. A GPCR can signal through multiple intracellular pathways, most commonly through G-proteins (like Gαs, Gαi, Gαq) or through β-arrestin recruitment.

• G-protein Pathways: Activation of the Gαs pathway, for example, leads to the production of cyclic AMP (cAMP), a crucial second messenger. This cAMP pathway is considered the "canonical" signaling route for the incretin and glucagon receptors and is the pathway most commonly measured in engineered cell lines expressing these receptors.
• β-arrestin Pathways: Alternatively, receptor activation can lead to the recruitment of β-arrestin proteins. While initially discovered for their role in desensitizing and internalizing GPCRs (turning the signal off), β-arrestins are now known to be signaling scaffolds themselves, initiating their own distinct downstream cellular responses, which can be independent of G-protein signaling.

The structural modifications of a synthetic peptide like glp-3-r determine its "bias profile." It might strongly activate the Gαs pathway (producing a large cAMP signal) while only weakly recruiting β-arrestin, or vice versa. This bias can differ for each of the three receptors it targets. For instance, glp-3-r could be a G-protein-biased agonist at the GLP-1R, a balanced agonist at the GIPR, and a β-arrestin-biased agonist at the GCGR.

Researchers are actively investigating these profiles using sophisticated in-vitro assays:

• cAMP Assays: These are used to quantify the production of cyclic AMP in cell lines (e.g., HEK293 or CHO cells) that have been engineered to express a specific receptor (GLP-1R, GIPR, or GCGR). By applying varying concentrations of glp-3-r, a concentration-response curve can be generated to determine the half-maximal effective concentration (EC50) and maximal response (Emax) for the G-protein pathway.
• β-arrestin Recruitment Assays: Techniques like Bioluminescence Resonance Energy Transfer (BRET) or Enzyme Fragment Complementation (EFC) are employed to measure the interaction between the activated receptor and β-arrestin in real-time within living cells. This allows for a direct quantification of the peptide's ability to engage this alternative pathway.

By comparing the concentration-response parameters from cAMP and β-arrestin assays, a "bias factor" can be calculated, giving a quantitative measure of a ligand's signaling preference relative to a reference agonist (Kenakin et al., 2012; Kenakin & Christopoulos, 2013). Structural work on GPCR complexes with G proteins and β-arrestins provides the molecular framework for interpreting these measurements (Krumm & Grisshammer, 2021). For a ligand characterized at three receptors, each receptor can show its own bias profile, so a complete description requires matched assays at every receptor, run with the same reference ligands, cell backgrounds and expression levels. Receptor expression level in particular strongly influences apparent activity in overexpression systems, so it should be documented and, where possible, held constant across the receptors being compared.

Practical Considerations for Multi-Receptor Assays

Several technical factors affect how reproducible multi-receptor data are:

• Cell background: HEK293 and CHO cells are common hosts, but endogenous receptor expression differs between lines. Parental-cell controls confirm that a signal depends on the transfected receptor.
• Assay kinetics: cAMP accumulation and β-arrestin recruitment develop on different time scales. Measuring at a single time point can bias comparisons, so time-course experiments are often run first.
• Peptide adsorption: Peptides can adsorb to plastic surfaces at low concentrations. Low-binding plates and tubes, and a carrier protein such as bovine serum albumin in assay buffer, are commonly used to limit losses.
• Reference ligands: Each receptor's native ligand, or a well-characterized reference agonist, should be included in every experiment for normalization.
• Replication: Independent experiments on different days, rather than replicate wells within one plate, provide the variance estimate used in statistical comparisons.

Common Assay Formats in Detail

Receptor pharmacology laboratories draw on a well-established set of assay technologies. Each measures a different step in the signaling sequence, and each has its own strengths and limitations:

• Homogeneous time-resolved fluorescence (HTRF) cAMP assays: A competitive immunoassay in which cellular cAMP displaces a labeled cAMP tracer, reducing an energy-transfer signal. These end-point assays are robust and suited to plate-based concentration-response work.
• Live-cell cAMP biosensors: Genetically encoded luminescent or fluorescent sensors report cAMP in real time, allowing kinetic measurements in the same well over tens of minutes.
• Reporter-gene assays: A cAMP response element (CRE) drives expression of a luciferase reporter. These assays integrate signaling over several hours and are highly sensitive, but they are further removed from the receptor and more prone to signal amplification.
• β-arrestin recruitment assays: BRET, split-luciferase (for example NanoBiT) and enzyme-fragment complementation formats measure the proximity of the receptor and β-arrestin in living cells.
• Receptor internalization assays: Surface-labeling or imaging methods quantify how much receptor leaves the cell surface after agonist exposure.
• Competition binding assays: A labeled reference ligand is displaced by increasing concentrations of the test peptide, yielding an inhibition constant (Ki) that reflects affinity rather than signaling.

Because amplification differs between formats, the same ligand can appear more or less active depending on the assay. For that reason, comparisons between receptors or between ligands should always use the same format, cell background and reference agonist.

Data Analysis and Reporting

Concentration-response data are usually fitted with a four-parameter logistic model to estimate EC50 (commonly reported as pEC50, the negative logarithm), Emax and the Hill slope. Emax is typically normalized to the maximal response of the reference agonist run in the same experiment. For bias analysis, many laboratories use the operational model of agonism, which estimates a transduction coefficient, log(τ/KA), for each pathway. Differences in this coefficient between a test ligand and a reference ligand (Δlog(τ/KA)), compared across two pathways (ΔΔlog(τ/KA)), provide a bias factor that is less sensitive to differences in assay amplification than simple EC50 ratios.

Clear reporting makes such data reusable. Useful elements include the cell line and its source, the receptor construct and expression level, the assay kit or sensor, incubation times and temperatures, the number of independent experiments, the curve-fitting model and software, and full identification of every ligand, including supplier, reference number and storage history. The COA reference for each ligand, and any independent analytical data obtained by the laboratory, should be reported as well.

Structural Studies of Class B GPCR Ligand Complexes

Since the late 2010s, cryo-electron microscopy has produced a series of structures of class B GPCRs bound to peptide ligands and heterotrimeric G proteins. These structures show the peptide's C-terminal region held by the extracellular domain and its N-terminal region reaching deep into the transmembrane bundle, where contacts with conserved residues trigger the outward movement of transmembrane helix 6 that opens the intracellular G-protein binding site. Comparing structures of the same receptor with different ligands, or of different receptors with the same ligand, is one of the main ways researchers relate peptide sequence to receptor selectivity at the molecular level. Synthetic peptide tools characterized across several receptors of the family contribute to this comparative structural work.

Comparative In-Vitro Profile: GLP-2T and GLP-3R

Excalibur Peptides catalogs two related research peptides used in receptor pharmacology: GLP-2T and GLP-3R. They differ mainly in the receptor panel over which they are characterized. The following table summarizes how they are used as laboratory tools.

Laboratories that keep both peptides can design stepwise experiments: single-receptor reference ligands, a two-receptor comparator and a three-receptor comparator, all tested in the same cell backgrounds with the same readouts. This kind of design isolates the contribution of each receptor to an observed signal in vitro and makes cross-laboratory comparison easier, provided each material is documented with its source, lot reference, storage history and preparation date.

GLP-2T was third-party tested by Freedom Diagnostics Testing (search code Exca2610050654), with purity by HPLC and identity by LC-MS, and GLP-3R was third-party tested by Freedom Diagnostics Testing (search code Exca2610050656), with purity by HPLC and identity by LC-MS; both COAs are published in the COA database. Recording each COA reference, and any incoming analysis, alongside the assay data strengthens any comparison between the two compounds.

A Researcher's Guide to Analytical Documentation: Interpreting a Certificate of Analysis (COA)

For any in-vitro study, the validity of the data depends on the identity, composition and integrity of the compounds used. A Certificate of Analysis is the document that records how a peptide was tested. Understanding what each test measures is a critical skill, whether a laboratory is reviewing a supplier's documentation or commissioning its own analysis of a research peptide. The sections below explain the key analytical tests and what their data mean.

1. High-Performance Liquid Chromatography (HPLC) for Purity Assessment

What it is: HPLC is the standard technique for assessing the chromatographic purity of a synthetic peptide. The technique separates the components of a mixture based on their chemical properties (such as hydrophobicity) as they pass through a column under high pressure. A small amount of the dissolved sample is introduced by an autosampler, and a detector, typically measuring UV absorbance at a specific wavelength (e.g., 214 nm, where the peptide backbone absorbs light), records the signal as components elute from the column.

How to Interpret the Data: The output is a chromatogram, a graph of signal intensity versus time.

• The Main Peak: The target peptide should produce a single, sharp, well-defined peak. The time at which this peak appears (the "retention time") is characteristic of the molecule under specific column and solvent conditions.
• Purity Calculation: The purity percentage is calculated by integrating the area under the main peak and dividing it by the total area under all detected peaks in the chromatogram.
• What to Look For: Peaks other than the main product peak represent impurities. These can be truncated fragments from incomplete synthesis, deletion sequences or stereoisomeric forms. The method conditions (column, gradient, detection wavelength) should be stated so that the reported figure can be interpreted and, if necessary, reproduced.

2. Identity Confirmation: Mass Spectrometry (MS) or FTIR

What it is: While HPLC confirms purity, an identity test confirms that the main component is the intended molecule. Two methods are common on peptide COAs. Mass spectrometry measures the mass-to-charge ratio (m/z) of ions: the glp-3-r peptide is ionized and then passed through a mass analyzer, which separates the ions based on their m/z. Fourier-transform infrared spectroscopy (FTIR) records the sample's infrared absorption spectrum, shaped by the peptide backbone and side-chain functional groups, and compares it with a reference spectrum for the compound.

How to Interpret the Data: The instrument produces a mass spectrum, a plot of ion intensity versus m/z.

• Molecular Weight: The theoretical molecular weight of a peptide is calculated from its amino acid sequence and any modifications. The mass spectrum should show a prominent peak corresponding to this expected molecular weight (or a multi-charged version of it, from which the true mass can be calculated).
• FTIR Spectrum: The sample spectrum should match the reference spectrum for the compound, including the amide I and amide II bands typical of a peptide backbone; the COA states whether identity was confirmed.
• What to Look For: A COA should report an identity result: for MS, a measured mass that matches the theoretical mass within a narrow tolerance; for FTIR, a spectral match to the reference. A significant deviation indicates that the synthesized peptide has the wrong amino acid sequence, an unintended modification, or is an entirely different substance. The GLP-3R COA published by Excalibur Peptides, issued by Freedom Diagnostics Testing, reports identity by LC-MS. Without an identity result, a researcher has no certainty of the compound's identity.

3. Endotoxin Testing (LAL Assay)

What it is: Endotoxins are lipopolysaccharides (LPS) from the outer membrane of Gram-negative bacteria. Even at very low concentrations they can activate innate immune signaling in cultured cells and produce non-specific responses that confound in-vitro data. The Limulus Amebocyte Lysate (LAL) test is an extremely sensitive assay used to detect and quantify endotoxin levels.

How to Interpret the Data: Values are typically reported in Endotoxin Units per milligram (EU/mg) or EU per vial.

• What to Look For: For cell-based applications, particularly those involving immune cells, endothelial cells or any cell type responsive to bacterial products, endotoxin content should be very low. Elevated endotoxin can cause unintended cytokine release or changes in cell viability that could be mistakenly attributed to the peptide under study.

4. Peptide Content and Counter-Ion Analysis

What it is: Lyophilized peptides are not composed solely of peptide. They are isolated as a salt, typically with acetate or trifluoroacetate (TFA) left over from purification, and they contain a small amount of water. Net peptide content analysis determines the fraction of the powder, by mass, that is peptide. It is often determined by amino acid analysis (AAA), elemental nitrogen analysis or quantitative NMR.

How to Interpret the Data: The COA should state the net peptide content as a percentage of total mass and identify the counter-ion.

• Why It Matters for Research: Net peptide content converts between the mass of powder weighed and the mass of peptide actually present. Failing to account for it causes systematic errors in any molar calculation, so the value reported on the documentation (or determined by the laboratory's own analysis) should always be used.

5. Additional Characterization Methods

Beyond the core tests, several further analyses can be commissioned when a laboratory needs a more complete picture of a synthetic peptide:

• Tandem Mass Spectrometry (MS/MS): The intact peptide ion is fragmented inside the instrument, and the resulting fragment ions (b- and y-series) are matched to the expected sequence. MS/MS confirms not only the total mass but also the order of amino acids, and it can locate modifications to specific residues.
• Amino Acid Analysis (AAA): The peptide is hydrolyzed to its constituent amino acids, which are then separated and quantified. AAA confirms composition and provides an absolute measure of peptide quantity, which is why it is widely used to determine net peptide content.
• Counter-Ion Analysis: Ion chromatography or 19F NMR quantifies residual trifluoroacetate, and ion chromatography can also quantify acetate. This is relevant for cell-based assays that are sensitive to TFA.
• Residual Solvent Analysis: Gas chromatography can detect solvents used in synthesis and purification, such as acetonitrile or diethyl ether, that may persist in trace amounts.
• Chiral Analysis: Racemization of individual residues during synthesis produces diastereomers that may co-elute with the main peak. Chiral amino acid analysis after hydrolysis can detect them.
• Orthogonal HPLC: Running a second HPLC method with a different column chemistry or mobile-phase pH can reveal impurities that co-elute with the main peak under the first method.

Not every study requires all of these analyses, but knowing they exist helps a laboratory decide what level of characterization its application needs, and what to request from an analytical service when a study needs more than a standard COA reports.

By reviewing documentation that covers HPLC purity, identity (LC-MS or FTIR), endotoxin and net peptide content, and by commissioning independent analysis where a study needs more, researchers reduce experimental risk and improve the reproducibility of their work.

Sourcing Integrity and the Critical Role of Storage

The journey of a research peptide from chemical synthesis to the laboratory bench involves several points at which its integrity can be compromised. Understanding that supply chain helps a laboratory judge the condition of the material on arrival and the validity of the data it later generates. Two stages matter most: synthesis and purification, and temperature control during storage before dispatch and after arrival.

Solid-Phase Peptide Synthesis (SPPS) and Purification

Most synthetic research peptides are produced by solid-phase peptide synthesis (SPPS). This well-established chemical method builds the peptide amino acid by amino acid on a solid polymer resin support.

1. Iterative Assembly: The process starts with the C-terminal amino acid anchored to the resin. Subsequent amino acids, with their reactive side chains chemically protected, are added one by one through repeated rounds of deprotection and coupling reactions.
2. Cleavage and Deprotection: Once the full-length sequence is assembled, the peptide is chemically cleaved from the resin support, and all the protecting groups are removed from the amino acid side chains.
3. Crude Product: This initial product is "crude" and contains the desired full-length peptide alongside various impurities, such as deletion sequences (where an amino acid was missed) and truncated sequences (from incomplete synthesis).
4. Purification: The crude mixture is then subjected to preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). This is a large-scale version of the analytical HPLC used for quality control. It separates the full-length peptide from the impurities. Fractions are collected and analyzed, and those meeting the target specification are pooled together.

Lyophilization: The Key to Stability

The purified peptide, now in a liquid solution containing solvents like acetonitrile and water with a counter-ion like acetic acid, must be converted into a stable, shippable form. This is achieved through lyophilization, or freeze-drying.

1. Freezing: The liquid peptide solution is frozen solid, typically at very low temperatures (-40°C to -80°C).
2. Primary Drying (Sublimation): Under a deep vacuum, the temperature is slightly raised, causing the frozen solvent (ice) to turn directly into a gas (sublimate) without passing through a liquid phase. This removes the bulk of the water.
3. Secondary Drying (Desorption): The temperature is raised further to remove any remaining, more tightly bound water molecules.

The product is a light, fluffy, white powder—the lyophilized peptide. This process is critical because it removes water, which is a key ingredient in chemical degradation pathways like deamidation and oxidation. A properly lyophilized peptide is significantly more stable than the same peptide in solution.

Frozen Storage Before Dispatch

While lyophilization confers a high degree of stability, it does not make the peptide indestructible. What happens between lyophilization and dispatch usually matters most: material that is frozen soon after production and kept frozen until it ships has spent little time at temperatures where slow degradation proceeds.

• Why it Matters: Even in a lyophilized state, high temperatures can accelerate slow degradation reactions, and certain amino acids are particularly sensitive. Heat can also promote aggregation, in which peptide molecules associate into insoluble forms. A prolonged temperature excursion, such as a package left in a hot vehicle, can compromise material and waste research time and funds.
• Questions to Ask a Supplier: How recently was the batch made? How is material stored before dispatch, and at what temperature? Is it held within the United States, and how long is the domestic transit? What storage conditions are recommended on arrival? Clear answers to these questions are part of the documentation that supports reproducible work.

When a researcher receives a peptide, the unopened vials should be transferred promptly to the storage condition listed for the product (2–8 °C for GLP-3R). Recording the date of receipt, the condition of the package and the storage location creates the first entry in the material's laboratory history.

Laboratory Storage, Handling and Documentation of Lyophilized GLP-3R

Good laboratory practice for a lyophilized research peptide centers on protecting the dry material from moisture, heat and repeated handling, and on keeping records that allow every experiment to be traced back to the material used. The practices below apply to the dry powder and to the documentation around it.

Step 1: Receiving and Logging

1. Inspect the package and vials. Check for damage, intact seals and caps, legible labels and a dry, uniform powder or pellet.
2. Match the label to the documentation. Confirm that the product name and any reference number on the vial correspond to the documentation on file.
3. Create an inventory record. Log the product name, supplier, date received, vial count, storage location and a reference to the documentation. This record will later be cited in methods sections.

Step 2: Storage Conditions

The lyophilized peptide is in its most stable state, and storage should keep it that way.

1. Temperature: Store sealed vials at 2–8 °C, as listed on the product page, in a unit that holds a stable temperature.
2. Moisture: Lyophilized peptides are hygroscopic. Keep vials sealed and, where practical, inside a secondary container with desiccant.
3. Light: Store vials in their carton or in an opaque box.
4. Monitoring: A temperature log or monitoring device for the storage unit documents that storage conditions were maintained throughout a project.

Step 3: Opening and Weighing

When material must be weighed, for example to prepare an analytical reference sample:

1. Equilibration: Allow the sealed vial to reach room temperature for 20 to 30 minutes before opening. Opening a cold vial lets atmospheric moisture condense on the powder, adding an unknown amount of water and compromising both stability and the accuracy of any weighed quantity.
2. Centrifugation: Briefly centrifuge the sealed vial so that any powder dislodged during shipping collects at the bottom, preventing loss when the cap is removed.
3. Weighing: Use a calibrated microbalance with static control, work quickly in low humidity, and reseal the vial promptly.
4. Net peptide content: Use the documented or independently determined net peptide content to convert between powder mass and peptide mass.

Step 4: Personal Protective Equipment and Hazard Information

Wear gloves, a lab coat and eye protection when handling any research peptide. Fine lyophilized powders can become airborne when a vial is opened, so weighing in a draft-shielded enclosure is good practice. Hazard and disposal information is provided on our Safety Data Sheets page.

Step 5: Traceability and Disposal

Record every time a vial is opened, the quantity removed and the purpose. When the material is used in an experiment, cite the supplier, product name, lot or reference number, storage history and any independent analytical data in the laboratory notebook and in the eventual methods section. Dispose of expired or unneeded material through the institution's chemical waste procedures, in accordance with the Safety Data Sheet and local regulations.

By following these storage and documentation practices, a laboratory ensures that the material it received remains well characterized throughout its experimental timeline, supporting accurate, reproducible and publishable data.

Expanded Frequently Asked Questions (FAQ)

1. What is the physical appearance of lyophilized glp-3-r?

Lyophilized glp-3-r should appear as a white, crystalline, or compacted solid pellet or powder at the bottom of the glass vial. The amount can often look very small (e.g., a 5mg vial may just have a small film or dot of material). This is normal. The lyophilization process removes water and solvents, which make up the vast majority of the pre-processed volume, leaving only the highly concentrated peptide salt. Do not judge the quantity by eye; rely on the mass specified on the vial label and, for molar calculations, on an independently determined net peptide content. The published GLP-3R COA (Freedom Diagnostics Testing (search code Exca2610050656)) reports the HPLC purity and the net peptide content measured for the sample tested, which is a useful starting point for that calculation.

2. Has GLP-3R been third-party tested?

Yes. GLP-3R was third-party tested by Freedom Diagnostics Testing (search code Exca2610050656), with purity by HPLC and identity by LC-MS. The Certificate of Analysis is published in the COA database, and the search code can be entered on the testing laboratory's COA lookup page. Laboratories whose work depends on a defined specification for the specific vial in use can also analyze the material by HPLC and an identity method, either in-house or through an analytical service, as part of incoming inspection, and record that analysis with their experimental data.

3. Why do HPLC and identity testing answer different questions?

HPLC separates the components of a sample and reports what proportion of the UV-absorbing material elutes as the main peak. An identity test confirms that the main component is the expected molecule: mass spectrometry (LC-MS) does this by measuring its molecular mass, and FTIR by matching its infrared spectrum to a reference. An HPLC trace alone cannot prove identity, because an unrelated compound could have a similar retention time, and an identity result alone cannot show how much of the sample is the target peptide. Together they establish both identity and composition.

4. What does an "acetate" or "TFA" salt form mean for glp-3-r experiments?

Research peptides are purified using RP-HPLC, which uses acidic mobile phases. To neutralize the peptide and create a stable, solid salt, a counter-ion is introduced. This is typically acetate (from acetic acid) or trifluoroacetate (TFA, from trifluoroacetic acid). Acetate is generally preferred as it is more "biocompatible" and less likely to have off-target effects in sensitive cell assays. TFA, being a stronger acid, can sometimes impact cell viability or pH at high concentrations. For most experiments, the concentration of the counter-ion in the final working solution is so low that it is biologically insignificant. However, it matters for any molar calculation, because the counter-ion contributes to the total powder weight. This is why the net peptide content figure should be used for accurate calculations. The GLP-3R COA reports HPLC purity, peptide content and FTIR identity for the sample tested; where the counter-ion content matters for a calculation, it can be confirmed by the laboratory's own analysis.

5. How should lyophilized GLP-3R be stored for a long project?

Store the sealed vials at 2–8 °C, as listed on the product page, protected from light and moisture. Keep vials in a secondary container with desiccant where practical, log the storage location, and record each opening. Allow vials to reach room temperature before opening so that condensation does not form on the powder.

6. What should be recorded when GLP-3R is used in an experiment?

At minimum: the supplier, product name, lot or reference number, date received, storage conditions, each date the vial was opened, the quantity used and any independent analytical data. This information allows the experiment to be traced back to the exact material and allows other laboratories to reproduce the work with comparable material.

7. What is the difference between glp-3-r and native glucagon or GLP-1?

The native ligands of the glucagon receptor family (glucagon, GLP-1 and GIP) are endogenous peptide hormones, and they are rapidly cleaved by proteases such as dipeptidyl peptidase-4 (DPP-4), which limits their stability in biological samples. GLP-3R is a synthetic research peptide that is characterized at all three receptors. In laboratory terms, the key differences are:

• Receptor profile: Each native hormone is characterized primarily at its own receptor, whereas GLP-3R is used to compare activity across the three receptors within one experimental design.
• Stability in assay conditions: Native hormones often require protease inhibitors in assay buffers. The stability of any synthetic peptide under a laboratory's specific assay conditions should be confirmed experimentally, for example by HPLC analysis of samples taken over the course of an incubation.
• Documentation: Native hormones used as reference ligands are typically sourced as well-characterized reference standards. Synthetic research peptides should be documented with their source, reference number and any analytical data.

8. What is the value of independent analytical testing?

Independent testing provides an impartial check on a material's identity and composition. A laboratory that has no commercial interest in the outcome of the analysis can confirm HPLC purity and identity (LC-MS or FTIR) objectively. That is why GLP-3R is tested by an independent laboratory, Freedom Diagnostics Testing, and why a laboratory's own incoming testing, recorded alongside experimental data, further strengthens the reproducibility of the work.

Glossary of Technical Terms

• Agonist: A molecule that binds to a receptor and activates it, producing a measurable cellular response.
• Beta-Arrestin: An intracellular protein recruited to activated GPCRs that regulates receptor desensitization and can act as a signaling scaffold.
• Biased Agonism: A phenomenon where an agonist, upon binding a GPCR, preferentially activates certain intracellular signaling pathways (e.g., G-protein) over others (e.g., β-arrestin).
• cAMP (Cyclic AMP): A second messenger produced by adenylyl cyclase when Gαs-coupled receptors are activated.
• Certificate of Analysis (COA): A document that records the analytical tests performed on a product and the data obtained.
• Class B GPCR: The secretin family of G protein-coupled receptors, characterized by a large N-terminal extracellular domain that binds peptide ligands.
• EC50: The concentration of a ligand that produces half of its maximal response in a given assay.
• Endotoxin: A lipopolysaccharide (LPS) component of the outer membrane of Gram-negative bacteria and a common contaminant in cell-based assays.
• GPCR (G-protein coupled receptor): A large family of transmembrane receptors that sense molecules outside the cell and activate internal signal transduction pathways, often via G-protein interaction. GLP-1R, GIPR and GCGR are all GPCRs.
• HPLC (High-Performance Liquid Chromatography): An analytical technique used to separate, identify and quantify each component in a mixture. It is the standard method for determining the chromatographic purity of a synthetic peptide.
• In-vitro: Performed in a test tube, culture dish or elsewhere outside a living organism. All research with GLP-3R is intended for in-vitro use only.
• LAL (Limulus Amebocyte Lysate) Test: An extremely sensitive assay used to detect the presence of endotoxins.
• Lyophilization: A freeze-drying process used to remove water from a product. It converts a peptide solution into a stable powder, increasing its shelf-life and simplifying shipping.
• Mass Spectrometry (MS): An analytical technique that measures the mass-to-charge ratio of ions. It is used to confirm the molecular weight, and therefore the identity, of a peptide.
• Net Peptide Content: The percentage of a lyophilized powder, by mass, that is peptide. The remainder consists of water and counter-ions from purification.

References

• Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC. Trends Pharmacol Sci. 2014;35(1):12-22.
• Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S. ACS Chem Neurosci. 2012;3(3):193-203.
• Kenakin T, Christopoulos A. Nat Rev Drug Discov. 2013;12(3):205-216.
• Krumm BE, Grisshammer R. Curr Opin Struct Biol. 2021;71:179-186.

Disclaimer: All products sold by Excalibur Peptides, including GLP-3R, are synthesized for and intended for in-vitro laboratory research purposes only. They are not intended for human or veterinary use of any kind. The information presented here is for educational and informational purposes for qualified researchers and laboratory professionals and describes in-vitro laboratory methods only. It should not be interpreted as an endorsement or recommendation for any form of use outside strictly controlled laboratory settings. It is the responsibility of the researcher to handle, store and use these compounds in accordance with established laboratory procedures and all applicable regulations. For any questions, please contact our support team at info@excaliburpeptides.com.